RT Journal Article SR Electronic T1 Risk factors for long COVID among healthcare workers, Brazil, 2020–2022 JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2023.01.03.22284043 DO 10.1101/2023.01.03.22284043 A1 Alexandre R. Marra A1 Vanderson Souza Sampaio A1 Mina Cintho Ozahata A1 Rafael Lopes Paixão da Silva A1 Anderson Brito A1 Marcelo Bragatte A1 Jorge Kalil A1 João Luiz Miraglia A1 Daniel Tavares Malheiros A1 Yang Guozhang A1 Vanessa Damazio Teich A1 Elivane da Silva Victor A1 João Renato Rebello Pinho A1 Adriana Cypriano A1 Laura Wanderly Vieira A1 Miria Polonio A1 Solange Miranda de Oliveira A1 Victória Catharina Volpe Ricardo A1 Aline Miho Maezato A1 Gustavo Yano Callado A1 Guilherme de Paula Pinto Schettino A1 Ketti Gleyzer de Oliveira A1 Rúbia Anita Ferraz Santana A1 Fernanda de Mello Malta A1 Deyvid Amgarten A1 Ana Laura Boechat A1 Takaaki Kobayashi A1 Eli Perencevich A1 Michael B. Edmond A1 Luiz Vicente Rizzo YR 2023 UL http://medrxiv.org/content/early/2023/01/05/2023.01.03.22284043.abstract AB Objectives We aimed to determine risk factors for the development of long coronavirus disease (COVID) in healthcare workers (HCWs).Methods We conducted a case-control study among HCWs who had confirmed COVID-19 infection working in a Brazilian healthcare system between March 1, 2020 and July 15, 2022. Cases were defined as those having long COVID per the Centers for Disease Control and Prevention definition. Controls were defined as HCWs who had documented COVID-19 infection but did not develop long COVID. Multiple logistic regression was used to assess the association between exposure variables and long COVID during 180 days of follow-up.Results Of 7,051 HCWs diagnosed with COVID-19 infection, 1,933 (27.4%) who developed long COVID were compared to 5,118 (72.6%) who did not. The majority of those with long COVID (51.8%) had 3 or more symptoms. Factors associated with development of long COVID were female sex (OR 1.21 [CI95 1.05-1.39]), age (OR 1.01 [CI95 1.00-1.02]), and two or more COVID-19 infections (1.27 [CI95 1.07-1.50]). Those infected with the Delta variant (OR 0.30 [CI95 0.17-0.50]) or the Omicron variant (OR 0.49 [CI95 0.30-0.78]), and those receiving four COVID-19 vaccine doses prior to infection (OR 0.05 [CI95 0.01-0.19]) were significantly less likely to develop long COVID.Conclusions Long COVID can be prevalent among HCWs. We found that acquiring more than one COVID-19 infection was a major risk factor for long COVID, while maintenance of immunity via vaccination was highly protective.Competing Interest StatementVSS, MCO, MB, AB, and JK are researchers at Instituto Todos pela Saude (ITpS), that funded this research.Funding StatementThis research received a grant from ITpS. VSS has a scholarship from Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq - PQ). ALB has scholarships from CNPq and ITpS. The sequencing reactions carried out to characterize the circulating SARS-CoV-2 described in this study were supported by grants 402669/2020-7 from Chamada MCTIC/CNPq/FNDCT/MS/SCTIE/ Decit 07/2020, Brazil and [ITpS] Termo de Cooperacao - Parceiros - ITpS x Hospital Albert Einstein [C2022-0751].   Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Hospital Israelita Albert Einstein Ethics Committee (CAAE 47110421.7.0000.0071) and the need for informed consent was waived.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript